Indian pharmaceutical industry stands on the cusp of a transformative leap, with artificial intelligence emerging as the key accelerator to secure global leadership in innovation and quality, asserted Prof Milind J Umekar, President of the Indian Pharmaceutical Congress Association and Chairman of the 74th IPC 2025.

Delivering insights at the upcoming flagship event, Prof Umekar emphasized that strategic AI deployment across R&D, manufacturing, regulatory compliance, and supply chains is rapidly shifting Indian pharma from volume-led generics to high-value, innovation-driven growth.

India’s world-class digital infrastructure combined with its deep pool of scientific talent uniquely positions the country to align faster with stringent international standards such as US FDA, EMA, and WHO-GMP, while simultaneously delivering better patient outcomes at lower costs.

In manufacturing, AI-enabled predictive maintenance systems are now anticipating equipment failures before they occur, slashing unplanned downtime and dramatically improving yields in continuous processing lines. Real-time smart quality systems analyse process data on the fly to detect deviations instantly, ensuring consistent product quality and seamless regulatory compliance.

On production lines, AI-powered computer vision systems inspect tablets, capsules, and packaging with accuracy far surpassing human capabilities, virtually eliminating defects, reducing recalls, minimizing material wastage, and accelerating the industry’s march toward fully compliant smart factories.

The impact extends powerfully into the medical devices segment, where AI is fuelling rapid development of intelligent diagnostic tools, smart wearables, and AI-assisted imaging systems. These innovations enable earlier disease detection, remote patient monitoring, and highly personalized therapies—while expanding the pharmacist’s role in patient-centric care and interdisciplinary coordination with clinicians.